- Home
- ERNA vs MRKR Comparison
ERNA vs MRKR Comparison
Compare ERNA & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ERNA
- MRKR
- Stock Information
- Founded
- ERNA 2018
- MRKR N/A
- Country
- ERNA United States
- MRKR United States
- Employees
- ERNA N/A
- MRKR N/A
- Industry
- ERNA Biotechnology: Pharmaceutical Preparations
- MRKR Biotechnology: Pharmaceutical Preparations
- Sector
- ERNA Health Care
- MRKR Health Care
- Exchange
- ERNA Nasdaq
- MRKR Nasdaq
- Market Cap
- ERNA 10.2M
- MRKR 11.6M
- IPO Year
- ERNA N/A
- MRKR N/A
- Fundamental
- Price
- ERNA $1.29
- MRKR $1.06
- Analyst Decision
- ERNA
- MRKR Strong Buy
- Analyst Count
- ERNA 0
- MRKR 3
- Target Price
- ERNA N/A
- MRKR $13.17
- AVG Volume (30 Days)
- ERNA 162.4K
- MRKR 304.6K
- Earning Date
- ERNA 11-11-2025
- MRKR 11-13-2025
- Dividend Yield
- ERNA N/A
- MRKR N/A
- EPS Growth
- ERNA N/A
- MRKR N/A
- EPS
- ERNA N/A
- MRKR N/A
- Revenue
- ERNA $488,000.00
- MRKR $5,388,071.00
- Revenue This Year
- ERNA N/A
- MRKR N/A
- Revenue Next Year
- ERNA N/A
- MRKR $9.35
- P/E Ratio
- ERNA N/A
- MRKR N/A
- Revenue Growth
- ERNA 201.24
- MRKR 44.55
- 52 Week Low
- ERNA $1.09
- MRKR $0.81
- 52 Week High
- ERNA $18.75
- MRKR $5.95
- Technical
- Relative Strength Index (RSI)
- ERNA 49.69
- MRKR 54.54
- Support Level
- ERNA $1.25
- MRKR $0.97
- Resistance Level
- ERNA $1.38
- MRKR $1.09
- Average True Range (ATR)
- ERNA 0.08
- MRKR 0.07
- MACD
- ERNA 0.02
- MRKR 0.02
- Stochastic Oscillator
- ERNA 63.47
- MRKR 69.48
About ERNA Eterna Therapeutics Inc.
Ernexa Therapeutics Inc is a biotechnology company. The company develops transformational new medicines using various cell engineering technologies for cancer and autoimmune diseases. The proprietary technology of the company transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), offering potential off-the-shelf treatment solutions without the need for patient-specific cell harvesting.
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.